Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9304034 | 1.00 | APLNR (0.33) | APLNR | |
| SCHEMBL2160578 | 1.00 | APLNR (0.33) | APLNR | |
| SCHEMBL9794756 | 0.84 | — | — | |
| SCHEMBL13619240 | 0.83 | — | — | |
| SCHEMBL16940575 | 0.81 | TRPA1 (0.31) | — | |
| SCHEMBL14380063 | 0.80 | — | — | |
| SCHEMBL4818781 | 0.80 | — | — | |
| SCHEMBL1804486 | 0.80 | — | — | |
| SCHEMBL6496533 | 0.80 | — | — | |
| SCHEMBL12432576 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265229-B2 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2007-09-04 | — | — | US | claimed |
| US-20060030720-A1 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | claimed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| EP-2780336-B1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | PASTEUR INSTITUT (FR) | 2017-07-19 | — | — | EP | disclosed |
| US-9598393-B2 | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | INSTITUT PASTEUR (FR) | 2017-03-21 | — | — | US | disclosed |
| US-9353077-B2 | Organocatalytic process for asymmetric synthesis of decanolides | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150210665-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-07-30 | — | — | US | disclosed |
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | INSTITUT PASTEUR (FR) | 2014-11-06 | — | — | US | disclosed |
| EP-2594561-A1 | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | INSTITUT PASTEUR (FR) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594561-A1 | Structural variants of mycolactones for use in modulating inflammation, immunity and pain | INSTITUT PASTEUR (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-7265229-B2 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265229-B2 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20060030720-A1 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20060030720-A1 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| WO-2004048360-A1 | METHOD OF SYNTHESIZING MACROSPHELIDES | LEAD CHEMICAL CO., LTD. (JP) | 2004-06-10 | — | — | WO | disclosed |
| US-5332807-A | Process of producing 8A- and 9A-azalide antibiotics | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1994015617-A1 | 8A-AZA AND 9A-AZA MACROLIDE ANTIBIOTICS, AND A PROCESS FOR PRODUCING SAME AND METHODS OF USE | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329771-A1 | STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN | IL1B, MYC, IL1A | APLNR 1429/4885 |
| US-20060030720-A1 | Method for synthesizing macrosphelides | ADH1C, HPD, HSD17B12 | APLNR 4600/4885 |
| US-20150210665-A1 | ORGANOCATALYTIC PROCESS FOR ASYMMETRIC SYNTHESIS OF DECANOLIDES | CDC14A, CDC14B, DDOST | APLNR 4238/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | APLNR 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.